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Abstract
Background: Toll-like receptors (TLR) 7 and 8 are important in single-stranded viral RNA recognition and may play
a role in HIV infection and disease progression. We analyzed TLR7/8 expression and signaling in monocytes from
HIV-infected and uninfected subjects to investigate a pathway with new potential for the suppression of HIV
replication.
Methods: Eighty-one HIV-infected and uninfected subjects from Liaoning and Henan provinces in China
participated in this study. Monocytes were isolated from subjects’ peripheral blood mononuclear cells by magnetic
bead selection. TLR7 and TLR8 mRNA was measured using quantitative real-time reverse transcriptase PCR. R-848
(resiquimod) was used as a ligand for TLR7 and TLR8 in order to 1) assess TLR7/8-mediated monocyte
responsiveness as indicated by IL-12 p40 and TNF-a secretion and 2) to examine HIV replication in cultured
monocytes in the presence of R-848.
Results: We found that expression of TLR7/8 mRNA in peripheral blood monocytes decreased with disease
progression. TLR7 expression was decreased with stimulation with the TLR7/8 agonist, R-848, in vitro, whereas TLR8
expression was unaffected. Following R-848 stimulation, monocytes from HIV-infected subjects produced
significantly less TNF-a than those from uninfected subjects, but trended towards greater production of IL-12 than
stimulated monocytes from uninfected subjects. R-848 stimulation also suppressed HIV replication in cultured
monocytes.
Conclusions: Our study provides evidence that the TLR7 and TLR8 triggering can suppress HIV replication in
monocytes and lead to postpone HIV disease progression, thereby offering novel targets for immunomodulatory
therapy.
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Background
Infection with HIV-1, the causative agent of AIDS, is
characterized clinically by a long asymptomatic period
of latency preceding the development of AIDS. Even
during this period of clinical latency, the virus replicates
continuously and causes new rounds of infection. In
recent years, many researchers have focused on adaptive
immune responses against HIV infection. To date, the
mechanisms that modulate HIV replication during this
clinically latent stage are not completely clear and stu-
dies of HIV immunotherapy and vaccination have not
shown great progress.
The importance of innate immunity in HIV infection
is becoming increasingly apparent [1-3]. Innate immu-
nity serves as the first line of defense against microbial
pathogens and is also responsible for the initiation of
inflammatory responses through the release of a variety
of cytokines, chemokines, and antimicrobial factors.
Monocytes, the precursors of macrophages and dendri-
tic cells, are involved in the innate immune response via
cognate interactions and production of proinflammatory
cytokines, such as interferons (IFNs), IL-12, IL-6 and
tumor necrosis factor alpha (TNF-a). In particular, toll-
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can signal cytokine release, cellular activation, and up-
regulation of the MHC Class I or Class II [4], and thus
help link the innate and the adaptive immune responses.
TLRs are a family of pattern recognition receptors that
mediate essential mechanisms of innate immunity against
microbial pathogens [5-7]. TLRs are grouped by their
preferences for conserved structural motifs of microor-
g a n i s m s .T L R 3 ,7 ,8 ,a n d9a r eimplicated in anti-viral
defense [5,8]. A recent study reported that TLR7/8 can
recognize uridine-rich ssRNA (ssRNA40) derived from
the HIV-1 long terminal repeat (LTR) [9], suggesting that
TLR7/8 may be involved in HIV infection as other inves-
tigators have previously reported [10,11].
It is still unknown whether TLR7/8 expression in
monocytes is related to disease progression in HIV-
infected patients or whether it represents a protective
factor in those patients who are slow disease-progres-
sors. Both TLR7 and 8 recognize single-stranded viral
RNA (ssRNA) [12,13], lead to NF-B activation [14],
and promote the production of cytokines such as IL-12
and TNF-a [15]. NF-B is critical for the transcription
of most immune response genes, inducing both types I
and II cytokines [16]. Ironically, there are NF-Bb i n d -
ing sites located within the HIV LTR [14] that can bind
NF-B and enhance HIV replication. Thus, the role of
TLR7/8 signaling in monocytes’ response to HIV repli-
cation merits further investigation.
In this study, we examined monocyte expression of
TLR7 and 8 mRNA from subjects with HIV over the
course of disease progression. We also assessed TLR7/8-
dependent cytokine secretion and HIV replication in
monocytes stimulated with the synthetic TLR7/8 ligand
R-848. We demonstrate that HIV disease progression is
influenced by TLR7/8 expression and signaling in
monocytes, offering additional targets in the pursuit of
treatments and cures for AIDS.
Methods
Study subjects
Sixty-three HIV-1-infected subjects from Liaoning and
Henan provinces in China were enrolled in the study.
All had been previously diagnosed using an anti-HIV
antibody screening test (Vironostika, Organon Tednika,
The Netherlands) which was confirmed by immunoblot-
based testing (Gene Lab Diagnostics, Singapore). HIV-
infected subjects were classified into three clinical
groups. Subjects in the first group were characterized as
“slow progressors” (SPs), with persistent CD4
+ cell
counts greater than 500 cells/μl, no anti-retroviral ther-
apy, and no clinical signs of disease for at least 10 years.
Subjects in the second group were characterized as
“chronic HIV infection subjects”, who had CD4
+ cell
counts between 200 and 500 cells/μl with no antiretro-
viral therapy and no AIDS-defining symptoms. Patients
in the third group were labeled “AIDS subjects”, consist-
ing of patients with < 200 CD4
+ cells/μla n d / o rt h e
appearance of opportunistic infections or AIDS-defining
symptoms according to the World Health Organization
classification. According to these criteria, the study
included 20 SPs, 25 chronic HIV infection subjects, 18
AIDS subjects and 18 HIV-negative healthy persons
(Table 1). All control subjects had normal blood cell
counts, normal levels of hemoglobin, and normal liver
function and did not have any history of immune system
disease. Blood samples from subjects were obtained
when opportunistic infection was not present. Samples
from HIV-infected and control subjects were always
handled in parallel. All subjects included here gave
informed consent and written approval was obtained
from the appropriate hospital ethics committees. All
investigations were conducted according to Helsinki
Declaration guidelines.
Isolation, culture, and stimulation of monocytes
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from buffy coats of heparinized blood by Ficoll-
Hypaque (Amersham Biosciences) density gradient cen-
trifugation; monocytes were further isolated using CD14
+-conjugated magnetic beads (Miltenyi Biotech, Ger-
many) for the positive selection according to the manu-
facturer’s instructions. The purity of the monocyte
population was > 97% as determined by flow cytometry
with phycoerythrin (PE)-conjugated anti-CD14 antibody
Table 1 Details of study subjects in each group
Study
group
Females/Males
(age)
a
CD4 Count (cells/
μl)
b
Plasma Viral Load (copies/
ml)
b
HCV Positive
n
c
HBV Positive
n
c
Receiving HAART
therapy n
c
SPs(20) 8/12 (47: 33-56) 637 (563-722) 47500 (24500-407750 5 0 0
HIV chronic
(25)
11/14 (44: 30-54) 411 (328-487) 11000 (2005-75000) 5 1 0
AIDS(18) 7/11 (48: 37-59) 107 (55-151) 4100 (790-16000) 4 1 4
Control(18) 9/9 (46: 36-54) 823 (524-1135) ND
d 00N D
d
a, Numbers of Females/Numbers of Males (median age in years: age interquartile range)
b, Median (interquartile range)
c, n, Positive Numbers
d, ND, not data
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Page 2 of 11(BD Pharmingen). Cell viability of monocytes at isola-
tion was > 90% as determined by trypan blue. Mono-
cytes were cultured in RPMI-1640 supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 25 mM
HEPES, 100 IU/ml penicillin G and 100 μg/ml strepto-
mycin, and were cultured at 5 × 10
5 cells/0.5 ml/well on
48-well flat bottom tissue culture plates following the
protocol described by Bekeredjian-Ding et al. [15]. The
antibiotics were added to prevent bacterial growth; cul-
tures grown in media lacking antibiotics did not display
different TLR7/8 expression. Monocytes were stimulated
with the TLR7/8 agonist R-848 (resiquimod, Alexis) at
2.5 μg/ml [15] or medium alone (controls) in cultures at
37°C, 5% CO2 for 24 h, at which point monocyte cyto-
kine secretion was fully functional and the levels of TLR
7/8 expression were also evaluated. Cell-free superna-
tants were harvested after a 24-h culturing period and
the concentrations of IL-12p40 (the bioactive form of
IL-12) and TNF-a were determined using an ELISA
assay (R&D and eBioscience, respectively). All supple-
mented media were found free of endotoxin (lack of
TNF-a induction in monocytes) [17]. HIV RNA load in
supernatant was also measured to assess viral replication
before and after culture of monocytes from HIV-
infected patients. Monocytes were washed three times
after separation and before culture; HIV RNA was not
detected in any initial monocyte culture. Monocytes
were cultured in 48 well plates with approximately 5 ×
10
5 cells/0.5 ml/well which was sufficient to produce
enough virus in 48 h to exceed detection limits [18].
HIV RNA load measurement
HIV-1 RNA levels in culture supernatants were
extracted from each sample with the Nuclisens extractor
(bioMérieux) and quantified using the Nuclisens EasyQ
(version 1.1) assay (bioMérieux) following the manufac-
turer’s instructions.
Determination of CD4
+ cell counts
CD4
+ cell counts were measured using a FACS Calibur
flow cytometer (Becton-Dickinson). A single-platform
lyse/no-wash procedure was performed using Trucount
tubes and TriTEST CD4-FITC/CD8-PE/CD3-PerCP
reagents (BD Biosciences).
Measurement of TLR7/8 mRNA expression
Total RNA was extracted from monocytes using the
RNeasy Protect Mini Kit (QIAGEN) according to the
manufacturer’s protocol. The concentration of total
RNA extracted from monocytes was determined by
measuring optical density at 260/280 nm. Reverse tran-
scriptase polymerase chain reaction was carried out
using a kit from the Takara according to the manufac-
turer’s protocol. The RT reaction consisted of 500 ng of
total RNA, 0.5 μl Oligo dT (50 μmol), 0.5 μlr a n d o m
hexamers (100 μmol), 2 μl 5 × PrimeScript Buffer,
adjusted to 10 μl with Rnase-Free dH2O. Reaction con-
ditions were set at 37°C for 15 min, 85°C for 5 s, and 4°
C until finished. The resulting cDNA was stored at -20°
C for subsequent polymerase chain reaction (PCR)
amplification. Expression analysis was performed using
quantitative real-time PCR with SYBR Green I (TakaRa,
Japan) on an ABI 7500 real time PCR system (Applied
Biosystem Inc., USA). Primers for TLR7 and TLR8 were
designed using Primer Express program (ABI) and their
specificity was examined with BLAST queries in the
National Center for Biotechnology Information (NCBI)
database. The following 5’ to 3’ oligoucleotides were
used: For TLR7, AATGTCACAGCCGTCCCTAC
(sense) and GCGCATCAAAAGCATTTACA (anti-
sense); for TLR8, TGTGATGGTGGTGCTTCAAT
(sense) and ATGCCCCAGAGGCTATTTCT (antisense).
Thermal cycler parameters included 40 cycles at 95°C (5
s) and 60°C (34 s). The dissolution curve conditions
were 95°C for 15 s, 60°C for 1 min, and 95°C for 15 s.
All gene-specific mRNA expression values were normal-
ized against the housekeeping gene, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). After amplification,
melting curves were generated automatically by the ABI
7500; only those showing a single high production peak
were considered to be valid amplifications. PCR amplifi-
cation of the RNA sample alone (without reverse tran-
scriptase treatment) was performed as a control; no
products of the TLR7/8 gene were detected indicating
that there was no relevant DNA contamination of the
RNA sample.
Statistical analysis
Data are depicted as means ± SEM or given as median
values (IQRs). All statistical tests used for data analysis
were performed using the SPSS Version 11.5 software
package (SPSS, Inc. Chicago). Differences among the
groups were compared using the Fisher’s least signifi-
cant difference test (LSD) and correlation was deter-
mined using the Pearson test for unpaired and normal
data. Differences between groups were compared using
the Mann-Whitney U test, and correlation was analyzed
using the Spearman rank test for unpaired and non-nor-
mal data. Wilcoxon signed rank tests were used for
comparisons of non-normal paired data. Probability
values were two-sided and considered to be significant
when p < 0.05.
Results
Expression of toll-like receptor 7/8 in peripheral blood
monocytes is associated with AIDS progression
To better understand the effect of HIV infection on the
expression of TLR7/8 in monocytes, total RNA was
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Page 3 of 11extracted from purified monocytes of HIV-infected sub-
jects and uninfected subjects; TLR7 and TLR8 mRNA
was then measured using real-time PCR. Figure 1A
shows that TLR7 mRNA levels in monocytes were sig-
nificantly increased in SPs versus uninfected subjects,
chronic HIV infection subjects, and AIDS subjects (p =
0.0483, p = 0.0473, and p < 0.0001 respectively), but
were significantly decreased in AIDS subjects in com-
parison to uninfected subjects (p = 0.0252) and chronic
HIV infection subjects (p = 0.0108). The expression of
TLR8 was significantly decreased in subjects with AIDS
compared with both uninfected subjects and SPs (p =
0.0414, p = 0.0169). No difference in TLR8 was seen
among SPs, chronic HIV infection subjects, and unin-
fected controls. In addition, we found that TLR7 and
TLR8 mRNA levels are significantly correlated with
CD4
+ cell counts (Figure 1B) (TLR7, r = 0.614, p <
0.0001; TLR8, r = 0.419, p = 0.0014). Taken together,
expression of TLR7 and TLR8 in monocytes was corre-
lated with AIDS disease progression and appeared to
decrease as with advancing severity of disease from SPs
to AIDS.
R-848 influence on toll-like receptor 7/8 expression in
monocytes in vitro
To determine if innate immune signals may play a role
in the decrease of TLR expression in monocytes in HIV
infection, we evaluated the effect of the TLR7/8 ligand,
R-848 (resiquimod) [19], on TLR7 and TLR8 expression
in cultured monocytes. R-848 functions as an analogue
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Figure 1 Expression of Toll-like receptor 7/8 in peripheral blood monocytes is associated with AIDS progression and correlates
positively with CD4
+ cell counts.( A) Expression of TLR7 was significantly increased in slow progressors (SPs) versus uninfected subjects,
chronic HIV infected subjects, and subjects with AIDS. TLR7 expression was also significantly increased in subjects with chronic HIV infection
versus AIDS. TLR7 in subjects with AIDS was significantly decreased compared to uninfected subjects. The expression of TLR8 was significantly
decreased in subjects with AIDS compared with both uninfected subjects and SPs,*p < 0.05. Comparisons were made with one-way ANOVA LSD
tests. All data are expressed as the mean ± SEM values from experiments performed in triplicate. (B) The expression of TLR7 and TLR8 was
significantly correlated with CD4
+ cell counts. Data was analyzed using the Spearman rank correlation with a level of significance of a = 0.05.
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Page 4 of 11of retroviral ssRNA to initiate signaling through both
TLR7 and TLR8. Monocytes from five HIV-infected and
three uninfected subjects were tested ex vivo (Table 2).
Stimulation with R-848 significantly decreased expres-
sion of TLR7 in monocytes derived from both HIV-
infected and uninfected subjects(p = 0.025). Treatment
with R-848 did not alter TLR8 expression (p = 0.944)
(Figure 2). Expression of TLR7/8 in monocytes from
either HIV-infected or uninfected subjects appears the
same (data not shown).
Response of TLR7 and TLR8 in monocytes contributes to
HIV infection
To assess whether alterations in TLR7 and TLR8
expression associated with HIV infection resulted in
altered TLR signaling, we compared the induction of
TNF-a and IL-12p40 by R-848 in monocytes from ten
chronic HIV infection subjects (Table 2) and nine unin-
fected subjects. Stimulation of monocytes with R-848
resulted in the significant production of TNF-a and IL-
12p40 compared with no production in media alone
(Figure 3A). Significantly lower TNF-a production was
seen in HIV-infected subjects compared with uninfected
subjects. The production of IL-12p40 trended towards
elevated expression but this increase was not significant.
Additionally, we analyzed the relationship between
TLR7 or TLR8 expression and production of these two
cytokines but found no correlation (data not shown).
Lack of correlation suggests that increased TLR7/8
expression does not result in increased cytokine secre-
tion. Therefore, we propose that increased TLR7/8
expression may enhance the cell’s ability to recognize
ssRNA of virions. Further studies are warranted to con-
firm our observations.
Interestingly, we found that the production of TNF-a
and IL-12p40 secreted by monocytes via TLR7/8 was
significantly correlated with CD4
+ cell counts in HIV-
infected individuals (Figure 3B). This data indicates that
CD4
+ cell counts could reflect TLR7/8-mediated mono-
cyte secretion function. So we observed the level of
TNF-a and IL-12p40 secretion of monocytes from sub-
jects of four groups in order to learn monocytes respon-
siveness during the HIV infection progression. We have
found that TNF-a and IL-12p40 secretions of triggered
monocytes were significant difference at each HIV infec-
tion disease stage (Figure 3D, *p < 0.05).
R-848 inhibits HIV replication in monocytes through the
TLR7/8 pathway
The correlation of monocyte cytokine secretion capa-
city with an individual’s HIV disease progression status
may imply a protective role for the TLR7/8 pathway.
We investigated whether the TLR7/8 pathway could
contribute to HIV replicationi nm o n o c y t e s ,s i n c es t u -
dies have shown that monocytes are considered under-
estimated HIV-1 viral reservoirs [20]. We first isolated
monocytes from nine chronic HIV-infected subjects
(Table 2) and cultured them for 48 h to assess the
ability of HIV to replicate in monocytes. HIV RNA
loads in the culture supernatants were found to be low
in six samples and were not detected in the other
three. We found that culture supernatants of mono-
cytes from subjects with CD4
+ cell counts < 400 cells/
μl had significantly higher HIV RNA loads than those
with > 400 cells/μl( F i g u r e4 ) .
R-848 has been found to be a TLR7/8 agonist with
demonstrated antiviral and anti-tumor activity [21,22].
Oral administration of R-848 has previously been
Table 2 Details of HIV infected subjects from whom monocytes were isolated and cultured ex vivo
Subject No.
a Sex (age)
c CD4 Count (cells/μl) CD8 Count (cells/μl) Plasma Viral Load (copies/ml) HCV
b HBV
b HIV Subtype
1 M(42) 332 1326 18800 P P CRF07-BC
2 F(38) 412 1373 92300 N N CRF01-AE
3 M(45) 368 463 71000 P N B
4 M(22) 484 1333 60100 N N B
5 M(40) 364 842 3200 N N CRF01-AE
6 M(46) 265 421 140000 N N CRF01-AE
7 M(33) 328 485 63000 N N CRF01-AE
8 F(45) 480 737 < 10 P N B’
9 F(45) 359 1064 3600 N P B’
10 M(32) 276 869 830000 P P B’
a Monocytes from subjects no.2,3,4,5,7 were used to analyze R-848 influence on expression of TLR7/8; Monocytes from subjects no.1-10 were used to examine
TLR7/8 signaling capacity; monocytes from subjects no.1-9 were used to examine HIV replication suppression mediated by TLR7/8. No subjects received HAART
therapy
b Minor or no biochemical signs of ongoing liver inflammation (alanine aminotransferase level < 70); P, Positive; N, Negative
c M, male; F, female; age in years
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Page 5 of 11tested against chronic HCV infection [23]. Importantly,
R-848 has been shown to block HIV replication in
acutely infected PBMCs by triggering TLR7/8 [24]. To
further understand whether the TLR7/8 triggering
could impact HIV replication in monocytes specifically,
we cultured monocytes from subjects with chronic
HIV infections with R-848 for 48 h and monitored
supernatant HIV RNA load as an indicator of HIV
replication. We found that HIV replication in culture
supernatants significantly decreased in five cases,
increased in one case, and showed no replication with
or without R-848 in the other three cases (Figure 5).
Cytokine levels and TLR mRNA were quantified in the
culture supernatant exhibiting increased HIV replica-
tion; TNF measured 1399 pg/ml, IL-12 measured 464
pg/ml, TLR 7 mRNA was 5.87 copies/μg, and TLR8
mRNA was 6.13 copies/μg (Subject #1 in Table 2).
Subject #1’s TLR functional status showed no distin-
guishing feature but his culture was infected with HIV
subtype (CRF07-BC). Whether this particular HIV sub-
t y p em a yb ea b l et oe s c a p eT L R7 / 8 ’s effect on replica-
tion merits further investigation.
Discussion
This study, to our knowledge, represents the first analy-
sis of the expression of TLR7/8 on monocytes during
HIV disease progression and the role of TLR7/8 trigger-
ing in monocytes on viral replication.
Monocytes are vital members of the innate immune
system as they are precursors to professional antigen
presenting cells (APCs). However, monocytes have been
implicated as a viral reservoir during HIV infection
based on the detection and recovery of replication-com-
petent virus from circulating monocytes isolated from
HIV-positive individuals [20,25,26]. In our study, we iso-
lated blood monocytes from nine HIV-infected subjects
and cultured the samples in vitro. Monocytes from six
of nine HIV-infected subjects exhibited HIV replication,
which indicates that peripheral blood monocytes of
HIV-infected patients contain replication-competent
HIV particles.
Recently, Almodovar et al. [27] reported that periph-
eral blood monocytes do not seem to be latent sources
of HIV in the presence of suppressive HAART (highly
active retroviral therapy); however, in the absence of
Figure 2 R-848 alters Toll-like receptor expression in vitro. Freshly isolated monocytes from uninfected (n =3 )a n dH I V - i n f e c t e d( n =5 )
subjects were cultured in the presence of R-848 or media alone for 24 h. TLR7/8 mRNA then quantified using real-time PCR. R-848 stimulation
significantly decreased expression of TLR7 in monocytes (
ap = 0.025) but did not alter TLR8 expression (
bp = 0.944). Data was analyzed using the
Wilcoxon signed ranks test. Bars indicate the interquartile range (IQR).
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Figure 3 Proinflammatory cytokine secretion mediated by TLR7/8 in monocytes varied based on HIV-infection status and correlated
positively with CD4
+ cell counts of peripheral blood in HIV-infected subjects. Ex vivo monocytes from uninfected (n = 10) and HIV-infected
(n = 10) subjects were cultured in the presence of TLR 7/8 ligand R-848 or media alone for 24 h. Culture supernatants were assessed for cytokine
levels using an ELISA assay. (A) R-848 stimulation produced significantly greater TNF-a production in monocytes of both HIV-infected and
uninfected subjects compared with unstimulated samples (p < 0.0001); stimulated uninfected subjects produced more TNF-a than stimulated HIV-
infected subjects (p = 0.0412). R-848 also induced significantly greater IL-12p40 production in monocytes of both HIV-infected (p < 0.0001) and
uninfected subjects compared with unstimulated monocytes (p < 0.0001). No statistically significant increase in IL-12p40 was observed in HIV-
infected versus uninfected subjects (P = 0.198). TNF-a levels were analyzed using the Mann-Whitney U two-tailed test. Independent t test were
used to analyze IL-12p40 levels. The significant differences are represented as p value (* p < 0.0001 compared with unstimulated by R-848, # p =
0.0412 compared with uninfected subjects). All data are expressed as the mean ± SEM values from experiments performed in triplicate. (B) Levels of
TNF-a and IL-12p40 secreted by monocytes via TLR7/8 were significantly correlated with CD4
+ cell counts in the ten HIV-infected individuals. (C)
TNF-a exhibited a significant positive correlation with IL-12p40 in HIV-infected individuals. Data was analyzed using a Pearson correlation.
Experiments were repeated at least 2 times with similar results. (D) The level of TNF-a and IL-12p40 secretions of triggered monocytes derived from
31 subjects belonging to the four categories (7 subjects of SPs, 10 of HIV Chronic, 7 of AIDS and 7 of Negative) were described (*p < 0.05).
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Figure 4 HIV RNA levels in monocyte culture supernatants are associated with peripheral blood CD4
+ cell counts. Monocytes isolated
from HIV-infected subjects (n = 9) were cultured in vitro. Supernatants in six subjects produced low levels of productive viral particles. HIV-
infected subjects were divided into two groups by CD4
+ cell count around a median of 400 cells/μl. HIV RNA levels (viral load, logarithmically
scaled) of each group are shown. The group with < 400 CD4
+ cells/μl had higher HIV replication levels than the group of > 400 CD4
+ cells/μl
(
ap = 0.0323). Data was analyzed using an independent t test.
Figure 5 HIV RNA levels in culture supernatants of monocytes were partially suppressed by R-848 via the TLR7/8 pathway. Monocytes
isolated from chronic HIV-infected subjects (n = 9) were cultured in vitro, of which six cases produced detectable low-level viral loads in the
culture supernatant. Viral loads of five cases significantly decreased in presence of R-848 (p = 0.0431) and increased in one case. The other three
cases had no detectable HIV replication with or without R-848 stimulation. Data was analyzed using the Wilcoxon signed-rank test were used
with a level of significance of a = 0.05. All data are expressed as the mean ± SEM from experiments performed in triplicate.
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with HIV. In our study, although all nine patients were
HAART-naïve, three did not show HIV replication
which suggests that inhibition of HIV replication may
be host-mediated [28,29]. However, we cannot rule out
that this result could be explained by our 48-h culture
protocol, which may have been insufficient to allow
detectable viral replication in these three samples.
Several studies have demonstrated that, even in indivi-
duals with viral loads suppressed below detection for
prolonged periods of time, HIV-1 still continues to
replicate at very low levels in monocytes and that
infected monocytes can transmit HIV-1 to other suscep-
tible cells [20,26,30]. Suppression or elimination of HIV
in infected subjects’ monocytes would be an important
method of preventing rebound infection. In our study,
we provide evidence that TLR7/8 triggering by the
TLR7/8 agonist, R-848, can suppress HIV replication in
monocytes. Moreover, a TLR7/8-initiated pathway can
induce a protective adaptive immune response that
leads to suppression of the pathogen [31-33], which
indicates that there are multiple roles for TLR7/8 in an
antiviral response.
The mechanism of HIV-1 latency in monocytes is not
fully understood. Given that the TLR7/8 receptors on
monocytes can recognize viral ssRNA and thus mediate
an antiviral immune response, we considered whether
the replication of HIV could be inhibited by triggering
the TLR7/8 signaling pathway. Our data demonstrate
that R-848 can inhibit HIV replication in monocytes
cultured from HIV-infected subjects, which suggests
that this inhibition is related to the TLR7/8 signaling
pathway and is dependent on monocytes themselves and
not on input from other cell types.
We also investigated whether inhibition of replication
could be related to the role of proinflammatory factors
secreted by monocytes after agonist stimulation. Several
studies have reported that TNF-a may induce HIV
replication in vitro [34,35]. Other studies have noted a
general increased in circulating TNF-a during HIV
infection [36,37] We compared HIV-infected and
healthy subjects by examining TNF-a and IL-12p40 in
monocyte culture supernatants. We observed reduced
TNF-a secretion by monocytes from HIV-infected
patients following stimulation with R-848. In this
respect, our results differ from previous results that
show increased monocyte TNF-a secretion due to sti-
mulation with gp120 and HIV virions [38-40]. As R-848
has a molecular structure similar to ssRNA, it is ideal
for studying TLR7/8 signaling. However, R-848 cannot
substitute for treatment with gp120 or complete HIV
virions. Other components of the HIV virion may pro-
vide a significant source of stimulus for innate immune
activation [41].
Among the six patients with positive HIV replication,
we found that patients with lower CD4
+ cell counts had
higher HIV replication levels, which supports the find-
ings of Innocenti et al. [42]. The higher HIV replication
levels indicated that the monocytes contained high levels
of HIV DNA as compared to monocytes from subjects
with high CD4
+ cell counts (which is an established
indicator of host immune status). Thus, we hypothesized
that TLR7/8 expression may vary HIV infection stage.
Indeed, we found that TLR7 and TLR8 expression
levels in monocytes declined as a function of the sever-
ity of HIV infection (i.e. slow progression to chronic
HIV infection to AIDS). TLR7 expression was decreased
significantly at each subsequent stage of HIV infection,
while TLR8 expression decreased significantly from
baseline levels only at the AIDS stage. Different levels of
TLR7/8 expression in different stages of HIV infection
suggest that their role in monocyte function also varies
according to HIV infection stage. To test this difference
further, we used the TLR7/8 ligand R-848 [19] to acti-
vate the TLR7/8 signaling pathway [43] in vitro. Our
findings show that TNF-a and IL-12p40 secretions were
decreased significantly at each subsequent HIV infection
stage, which indicated that the decreased TLR7 expres-
sion of monocytes should be linked to a lower response
to R-848. Meanwhile, our findings also show that TLR7
expression levels are decreased significantly after mono-
cytes are stimulated by R-848 in vitro, which corre-
sponds to the observed pattern of TLR7 expression
levels in monocytes across disease progression stages.
This data suggests that TLR7 is more responsive and
hypersensitized to its ligands, while TLR8 expression in
monocytes in vitro was stable after stimulation with R-
848, which corresponds to the conserved in vivo TLR8
expression in monocytes of subjects from the SPs and
HIV chronic stages. Hence this study reveals differences
in TLR7 and TLR8 expression in monocytes from HIV-
infected subjects both in vivo and after in vitro stimula-
tion; however, further studies are needed to elucidate a
mechanistic explanation of altered TLR expression in
HIV-infected monocytes.
TLR 7/8 may recognize HIV ssRNA. Binding of the
appropriate ligands results in the recruitment of the
adaptor protein Myeloid Differentiation Factor 88
(MyD88)followed by various IL-1 receptor-associated
kinase (IRAK) family members. TNF receptor-associated
factor 6 (TRAF6) is also recruited and finally the NF-B
and mitogen-activated protein kinases (MAPKs) are acti-
vated. These events result in the induction of inflamma-
tory cytokines and chemokines [44]. Thus, TLR 7
binding to its ligand could result in the production of
cytokines; decreased TLR 7 expression would theoreti-
cally lead to a drop in cytokine secretion. However, our
study found no correlation between TLR expression and
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Page 9 of 11TNF or IL-12 secretion (data not shown). We speculate
that the expression level of TLR 7 may influence the fre-
quency with which ligands are recognized; the higher
the level of TLR expression, the greater chance that a
ligand such as ssHIV RNA will be detected.
Our study demonstrates that TLR 7/8 activation elicits
an antiviral response in primary monocytes with
increased TLR 7 expression at the initial disease (SP
stage); thus, we can speculate that at the time of initial
HIV-infection, HIV ssRNA may be recognized by TLR 7
and activate signaling pathways resulting in MyD88 acti-
vation and subsequent production of proinflammatory
cytokines such as IFNs which could increase TLR 7/8
expression [45]. Persistent immune activation in HIV is
thought to contribute to pathogenesis by progressively
disturbing cytokine expression, functional organization
of the immune system [46], and decreasing TLR expres-
sion (AIDS stage). Further studies are needed to exam-
ine this possibility. Interestingly, our observation of
decreased TLR7 and TLR8 mRNA expression in mono-
cytes differs from the increase in TLR7 and TLR8
mRNA expression as Lester et al. reported [47] in
PBMCs, which suggests that monocytes experience a
unique change in TLR7/8 expression distinct from other
PBMCs.
Our study is preliminary and since it is performed in
restricted conditions its extrapolation to clinical applica-
tions is challenging. It has several limitations. First, the
number of cases is limited and this should be taken into
consideration when interpreting the results. Neverthe-
less, to our knowledge, no other study has reported that
R-848 inhibited HIV replication specifically in mono-
cytes nor have other studies documented the association
between TLR7/8 expression in monocytes and HIV dis-
ease progression. Second, TLR7/8 expression was only
measured at the mRNA level; analysis of protein levels
will increase our understanding of the phenomenon.
However, Song et al. [10] have confirmed that enhanced
expression of TLR7 mRNA in CD8
+ T cells corresponds
to increased TLR7 protein expression. Finally, we have
not yet undertaken sophisticated mechanistic studies of
the variations in TLR7/8 signaling pathway which may
occur during progressive stages of HIV infection.
Conclusions
Our study reveals a relationship between TLR7/8 mRNA
expression levels in monocytes and HIV disease progres-
sion. Furthermore, our data indicate that HIV replica-
tion can be suppressed via TLR7/8 ligation in vitro.
Further analysis of the TLR7 and TLR8 pathway may
contribute to the understanding of the immunopatho-
genesis of HIV infection and may ultimately offer novel
targets for immunomodulatory therapy.
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